TR
Investor profile
Third Rock Ventures
Venture Capital · Founded 2007 · Boston, United States
72 portfolio companies
Venture Capital · $8.6B invested · 138 investments · Investor rank #326 · Last investment 6/2026
Portfolio companies
72
↑ 29% 5y
Decacorns
2
Thoroughbreds
10
01 · Exits
Third Rock Ventures’ biggest exits.
Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from Third Rock Ventures’ transaction record.
$1.4B IPO · 2020
IPO · 2015
$398M IPO · 2015
$443M IPO · 2017
Global Blood Therapeutics
$350M IPO · 2015
$500M IPO · 2013
$167M IPO · 2021
$1.7B IPO · 2020
IPO · 2018
$2.1B acquisition · 2020
IPO · 2020
Candid Therapeutics
$2.0B acquisition · 2026
02 · Portfolio analysis
Where Third Rock Ventures’ portfolio is concentrated.
Distribution of portfolio companies by headquarters country, sector, entry stage and current growth stage. Across all 72 portfolio companies. "Stage entered" is the first priced round the investor joined, derived from the investor’s transaction history.
By countryCount
-
USA70
-
Belgium1
-
Germany1
-
Singapore1
By sectorCount
-
Health71
-
Enterprise Software1
-
Fintech1
-
Media1
By stage enteredCount
-
Series A59
-
Series B+10
-
Seed3
By growth stageCount
-
Late Growth54
-
Breakout Stage15
-
Early Growth3
-
Mature1
03 · Portfolio market map
Inside Third Rock Ventures’ portfolio.
The 60 highest-funded portfolio companies, of 72 tracked.
JoJohnson & Johnson Innovative Medicine
MaMaze Therapeutics
$140M
InInsitro
$1.6B
ReRelay Therapeutics
$3.5B
CoConstellation Pharmaceuticals
$1.7B
CaCandid Therapeutics
$2.0B
ThThrive Earlier Detection
$2.2B
TeTerremoto Biosciences
$875M
TaTango Therapeutics
$4.1B
EdEditas Medicine
$246M
SeSeaport Therapeutics
$989M
FlFlare Therapeutics
$340M
RaRapport Therapeutics
$1.8B
SeSepterna
$1.4B
ARARTBIO
$528M
MoMoma Therapeutics
$600M
CoCorvia Medical
$220M
NeNeon Therapeutics
$67M
ReRevolution Medicines
$41B
AsAsher Bio
$540M
PlPliant Therapeutics
CACARGO Therapeutics
MaMarea Therapeutics
$570M
AbAbata Therapeutics
$380M
DeDecibel Therapeutics
$58M
ElElement Science
$582M
NuNurix
$2.0B
CyCytomX Therapeutics
$430M
CaCasma Therapeutics
$293M
BlBluebird bio
$150M
GoGoldfinch Biopharma
$400M
MaMagenta Therapeutics
ClClasp Therapeutics
$600M
FuFulcrum Therapeutics
SySynnovation Therapeutics
$408M
CeCedilla Therapeutics
$288M
ZaZafgen
$347M
KAKALA BIO
$6.7M
MoMorphoSys
$2.7B
WaWarp Drive Bio
$238M
RhRhythm Pharmaceuticals
$7.8B
MeMerida Biosciences
$484M
AgAgios Pharmaceuticals
$1.3B
NiNinePoint Medical
$123M
BlBlueprint Medicines
$8.3B
TATARIS Biomedical
$100M
PaPanOptica
$44M
AmAmbys Medicines
$300M
VoVoyager Therapeutics
$118M
JoJounce Therapeutics
TrTrace Neuroscience
$404M
FoFoundation Medicine
$5.3B
AlAlcresta
$40M
SASAGE Therapeutics
$191M
AlAllena Pharmaceuticals
$100M
SeSeventh Sense Biosystems
$84M
GlGlobal Blood Therapeutics
$5.4B
AfAfferent Pharmaceuticals
$220M
CeCelsius Therapeutics
$250M
AzAzalea Therapeutics
$260M
04 · Portfolio founders
Where Third Rock Ventures’ portfolio founders come from.
103 founders across the 73 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.
LocationCount
-
United States88
-
Germany2
-
United Kingdom2
-
France1
-
Singapore1
-
Switzerland1
UniversityCount
-
Harvard University9
-
Massachusetts Institute of Technology5
-
Harvard Medical School4
-
Stanford University4
-
Stanford University School of Medicine2
-
University of Heidelberg2
-
Wharton School of the University of Pennsylvania2
-
Allegheny College1
-
Bard College1
-
Brown University1
Previous companyCount
-
Third Rock Ventures5
-
Pfizer4
-
Biogen2
-
Constellation Pharmaceuticals2
-
Dana-Farber Cancer Institute2
-
Genentech2
-
Merck & Co.2
-
Stanford University2
-
Stanford University School of Medicine2
-
Technology Transfer Center2
05 · Similar investors
Similar investors.
Peers the API surfaces as most similar by portfolio shape, with Dealroom investor rank and portfolio scale.
Khosla Ventures
#53 rank
856 companies
$1.9T portfolio
Eurazeo
#97 rank
375 companies
$159B portfolio
Fidelity Investments
#7 rank
363 companies
$6.1T portfolio
NEA
#36 rank
1,186 companies
$2.5T portfolio
Venrock
#101 rank
392 companies
$5.8T portfolio
T. Rowe Price
#4 rank
216 companies
$4.7T portfolio
ARCH Venture Partners
#67 rank
251 companies
$515B portfolio
Seventure Partners
#737 rank
199 companies
$74B portfolio
06 · Key people
Key people at Third Rock Ventures.
Kevin Starr
COO
Neil Exter
Partner
Chris Robinson- Chief Talent Officer
Director
Jeffrey Tong
Partner
Reid Huber
Partner
Alan Ezekowitz
Partner
Jigar Raythatha
Partner
Mark Levin
Partner
Source: Dealroom next-gen API — investor team endpoint.
